留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

免疫治疗在肝细胞癌治疗中的进展

郭玲玲,  仇金荣

downloadPDF
文章导航 > 药学实践与服务  > 2017 >  35(4): 362-366
郭玲玲, 仇金荣. 免疫治疗在肝细胞癌治疗中的进展[J]. 药学实践与服务, 2017, 35(4): 362-366. doi: 10.3969/j.issn.1006-0111.2017.04.019
引用本文: 郭玲玲, 仇金荣. 免疫治疗在肝细胞癌治疗中的进展[J]. 药学实践与服务, 2017, 35(4): 362-366. doi: 10.3969/j.issn.1006-0111.2017.04.019
shu
GUO Lingling, QIU Jinrong. Progress in immunotherapy for hepatocellular carcinoma[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(4): 362-366. doi: 10.3969/j.issn.1006-0111.2017.04.019
Citation: GUO Lingling, QIU Jinrong. Progress in immunotherapy for hepatocellular carcinoma[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(4): 362-366. doi: 10.3969/j.issn.1006-0111.2017.04.019
shu

免疫治疗在肝细胞癌治疗中的进展

doi: 10.3969/j.issn.1006-0111.2017.04.019

  • 第二军医大学附属东方肝胆外科医院肿瘤生物治疗科, 上海 200438

Progress in immunotherapy for hepatocellular carcinoma

  • Division of Biological Therapies for Cancer, Eastern Hepatobiliary Surgery Hospital Affiliated to Second Military Medical University, Shanghai 200438, China

  • 摘要: 肝细胞癌（HCC）是全球发病率和致死率都很高的恶性肿瘤。目前以手术治疗为主的治疗方法远难以达到理想的效果。肿瘤免疫治疗，包括树突状细胞诱导的杀伤细胞（DC-CIK）、肿瘤浸润淋巴细胞（TIL）、嵌合抗原受体T细胞（CAR-T）、免疫检查点阻滞剂（如PD-1阻滞剂、CTL4阻滞剂）等，是近年发展迅速且具有良好前景的肿瘤治疗新方法。本综述着重介绍PD-1阻滞剂、DC-CIK细胞、TIL细胞在治疗肝细胞癌中取得的进展，并对本课题组发明的多能免疫杀伤转基因细胞（PIK）做简要介绍。
    Abstract: Hepatocellular carcinoma is a malignant tumor with high morbidity and mortality globally. The therapeutic results on hepatocellular carcinoma with surgery and other classical treatments are not satisfactory. Tumor immunotherapies, such as dendritic cells and cytokine-induced killer cells (DC-CIK), tumor-infiltrating lymphocytes (TIL), chimeric antigen receptor T cells (CAR-T), immune checkpoint blockade (such as PD-1 blockade,CTL4 blockade) etc., are very promising new therapeutic approaches. In this paper, the progresses in the immunotherapy, mainly on PD-1, DC-CIK, TIL, are reviewed. Also pluripotent immune killer cells (PIK) which was developed in our lab was briefly introduced.
  • [1] Torre LA, Bray F, Siegel RL,et al. Global cancer statistics,2012[J]. CA Cancer J Clin,2015,65(2): 87-108.
    [2] Car BI. Hepatocellular carcinoma: current management and future trends[J]. Gastroenterology,2004,127(5 Suppl 1): S218-224.
    [3] Llovet JM, Ricci S, Mazzaferro V,et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med,2008,359(4): 378-390.
    [4] Killock D. Liver cancer: Regorafenib-a new RESORCE in HCC[J]. Nat Rev Clin Oncol, 2017, 14(2): 70-71.
    [5] Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy[J]. Science,2013,342(6165): 1432-1433.
    [6] Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial[J]. Lancet,2014,384(9948): 1109-1117.
    [7] Robert C, Schachter J, Long GV,et al. Pembrolizumab versus ipilimumab in advanced melanoma[J]. N Engl J Med,2015,372(26): 2521-2532.
    [8] Garon EB, Rizvi NA, Hui R,et al. Pembrolizumab for the treatment of non-small-cell lung cancer[J]. N Engl J Med,2015,372(21): 2018-2028.
    [9] Harding JJ, El Dika I, Abou-Alfa GK. Immunotherapy in hepatocellular carcinoma: Primed to make a difference[J]. Cancer,2016,122(3): 367-377.
    [10] Gravitz L. Cancer immunotherapy[J]. Nature, 2013,504(7480): S1.
    [11] Kim HM, Lim J, Yoon YD,et al. Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma[J]. Int Immunopharmacol,2007,7(13): 1793-1801.
    [12] Schmidt-Wolf IG, Negrin RS, Kiem HP,et al. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity[J]. J Exp Med,1991,174(1): 139-149.
    [13] Banchereau J, Steinman RM. Steinman. Dendritic cells and the control of immunity[J]. Nature,1998, 392(6673): 245-252.
    [14] Zhang L, Zhu W, Li J,et al. Clinical outcome of immunotherapy with dendritic cell vaccine and cytokine-induced killer cell therapy in hepatobiliary and pancreatic cancer[J]. Mol Clin Oncol,2016,4(1): 129-133.
    [15] Lin T, Song C, Chuo DY,et al. Clinical effects of autologous dendritic cells combined with cytokine-induced killer cells followed by chemotherapy in treating patients with advanced colorectal cancer: a prospective study[J]. Tumour Biol,2016,37(4): 4367-4372.
    [16] Wang S, Wang Z. Efficacy and safety of dendritic cells co-cultured with cytokine-induced killer cells immunotherapy for non-small-cell lung cancer[J]. Int Immunopharmacol,2015,28(1): 22-28.
    [17] Jiang JT, Shen YP, Wu CP,et al. Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients[J]. World J Gastroenterol,2010,16(48): 6155-6162.
    [18] Hui D, Qiang L, Jian W,et al. A randomized,controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma[J]. Dig Liver Dis,2009,41(1): 36-41.
    [19] Pan K, Li YQ, Wang W,et al. The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients[J]. Ann Surg Oncol, 2013,20(13): 4305-4311.
    [20] Xie F, Zhang X, Li H,et al. Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review[J]. PLoS One,2012,7(8): e42879.
    [21] Niu LZ, Li JL, Zeng JY,et al. Combination treatment with comprehensive cryoablation and immunotherapy in metastatic hepatocellular cancer[J]. World J Gastroenterol,2013,19(22): 3473-3480.
    [22] Cui J, Wang N, Zhao H,et al. Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma[J]. Int J Cancer,2014,134(2): 342-351.
    [23] Hao MZ, Lin HL, Chen Q,et al. Efficacy of transcatheter arterial chemoembolization combined with cytokine-induced killer cell therapy on hepatocellular carcinoma: a comparative study[J]. Chin J Cancer,2010,29(2): 172-177.
    [24] 郭伟伟, 刘 莉, 吴德华. DC-CIK细胞免疫治疗联合TACE术治疗原发性肝癌[J]. 南方医科大学学报,2014,34(5): 674-678.
    [25] He G, Zheng C, Huo H,et al. TACE combined with dendritic cells and cytokine-induced killer cells in the treatment of hepatocellular carcinoma: A meta-analysis[J]. Int Immunopharmacol,2016,40: 436-442.
    [26] Rosenberg SA, Restifo NP, Yang JC,et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy[J]. Nat Rev Cancer,2008,8(4): 299-308.
    [27] Shirabe K, Motomura T, Muto J,et al. Tumor-infiltrating lymphocytes and hepatocellular carcinoma: pathology and clinical management[J]. Int J Clin Oncol,2010,15(6): 552-558.
    [28] Jiang SS, Tang Y, Zhang YJ,et al. A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma[J]. Oncotarget,2015,6(38): 41339-41349.
    [29] Dolan DE, Gupta S. PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy[J]. Cancer Control,2014,21(3): 231-237.
    [30] Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms,response biomarkers,and combinations[J]. Sci Transl Med,2016, 8(328): 328rv324.
    [31] Wu K, Kryczek I, Chen L,et al. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions[J]. Cancer Res,2009,69(20): 8067-8075.
    [32] Finkelmeier F, Canli Ö, Tal A,et al. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis[J]. Eur J Cancer,2016,59: 152-159.
    [33] Gao Q, Wang XY, Qiu SJ,et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma[J]. Clin Cancer Res,2009,15(3): 971-979.
    [34] Kuang DM, Zhao Q, Peng C,et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1[J]. J Exp Med,2009,206(6): 1327-1337.
    [35] Ouyang FZ, Wu RQ, Wei Y,et al. Dendritic cell-elicited B-cell activation fosters immune privilege via IL-10 signals in hepatocellular carcinoma[J]. Nat Commun,2016,7: 13453.
    [36] Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer[J]. Nature,2014,515(7528): 558-562.
    [37] Brahmer JR, Tykodi SS, Chow LQ,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer[J]. N Engl J Med,2012,366(26): 2455-2465.
    [38] Armand P, Nagler A, Weller EA,et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase Ⅱ trial[J]. J Clin Oncol,2013,31(33): 4199-4206.
    [39] Westin JR, Chu F, Zhang M,et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group,open-label,phase 2 trial[J]. Lancet Oncol,2014,15(1): 69-77.
    [40] Ansell SM, Lesokhin AM, Borrello I,et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma[J]. N Engl J Med,2015,372(4): 311-319.
    [41] Herbst RS, Soria JC, Kowanetz M,et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients[J]. Nature,2014,515(7528): 563-567.
    [42] El-Khoueiry A B, Melero I, Crocenzi T S, et al.Phase Ⅰ/Ⅱ safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040[J]. Clin Oncol 2015,33(18): LBA101.
    [43] Chen CL, Pan QZ, Zhao JJ,et al. PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma[J]. Oncoimmunology,2016,5(7): e1176653.
    [44] Le DT, Uram JN, Wang H,et al. PD-1 blockade in tumors with mismatch-repair deficiency[J]. N Engl J Med,2015,372(26): 2509-2520.
    [45] Sun TW, Gao Q, Qiu SJ,et al. B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence[J]. Cancer Immunol Immunother,2012,61(11): 2171-2182.
    [46] Pan QZ, Wang QJ, Dan JQ,et al. A nomogram for predicting the benefit of adjuvant cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma[J]. Sci Rep,2015,5: 9202.
    [47] Tang H, Qiao J, Fu YX. Immunotherapy and tumor microenvironment[J]. Cancer Lett,2016,370(1): 85-90.
    [48] Sivan A, Corrales L, Hubert N,et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy[J]. Science,2015,350(6264): 1084-1089.
    [49] Vétizou M, Pitt JM, Daillère R,et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota[J]. Science,2015,350(6264): 1079-1084.
    [50] Wang XP, Xu M, Gao HF,et al. Intraperitoneal perfusion of cytokine-induced killer cells with local hyperthermia for advanced hepatocellular carcinoma[J]. World J Gastroenterol,2013, 19(19): 2956-2962.
    [51] Qiu Y, Xu MB, Yun MM,et al. Hepatocellular carcinoma-specific immunotherapy with synthesized alpha1,3- galactosyl epitope-pulsed dendritic cells and cytokine-induced killer cells[J]. World J Gastroenterol,2011,17(48): 5260-5266.
  • [1] 黄韵, 张正银, 金英, 郑怡菁, 李铁军, 孙莉莉.  耐碳青霉烯类肺炎克雷伯菌及大肠埃希菌临床分离株耐药性及耐药基因分析 . 药学实践与服务, 2024, 42(10): 439-444. doi: 10.12206/j.issn.2097-2024.202309059
    [2] 孙丹倪, 黄勇, 张嘉宝, 王培.  代谢相关脂肪性肝病的无创诊断与药物治疗 . 药学实践与服务, 2024, 42(10): 411-418. doi: 10.12206/j.issn.2097-2024.202403049
    [3] 张晶晶, 索丽娜, 郑兆红.  89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
    [4] 王雪莲, 郑斯莉, 李志勇, 罗亨宇, 缪朝玉.  全身过表达人METRNL基因小鼠模型的构建与验证 . 药学实践与服务, 2024, 42(5): 198-202, 222. doi: 10.12206/j.issn.2097-2024.202311014
    [5] 陈莹, 许子华, 胡北, 崔亚玲, 高欢, 吴琼.  通便灵胶囊治疗便秘的药效与机制研究 . 药学实践与服务, 2024, 42(): 1-7. doi: 10.12206/j.issn.2097-2024.202404008
    [6] 宋泽成, 陈林林, 鲁仁义, 刘梦肖, 王彦.  脓毒症治疗的研究进展 . 药学实践与服务, 2024, 42(11): 457-460, 502. doi: 10.12206/j.issn.2097-2024.202405059
    [7] 姚瑞阳, 于海征, 李耀盺, 张磊.  丹参FBXL 基因家族的鉴定和表达模式分析 . 药学实践与服务, 2024, 42(11): 461-470. doi: 10.12206/j.issn.2097-2024.202407034
    [8] 岳春华, 贲永光, 王海桥.  基于NLRP1炎症小体探讨百合知母汤抗抑郁的作用机制 . 药学实践与服务, 2024, 42(8): 325-333. doi: 10.12206/j.issn.2097-2024.202401033
    [9] 李想, 陆鸿远, 张明玉, 高欢, 姚东, 许子华.  米格列醇激活UCP1介导棕色脂肪对冷暴露小鼠损伤的研究 . 药学实践与服务, 2024, 42(): 1-6. doi: 10.12206/j.issn.2097-2024.202404005
    [10] 顾佳钰, 胡馨儿, 王晓飞, 张颖, 张海, 曹岩.  侧流免疫层析定量检测方法的研究进展 . 药学实践与服务, 2024, 42(7): 273-277, 284. doi: 10.12206/j.issn.2097-2024.202307037
    [11] 冯志惠, 邓仪卿, 叶冰, 安培, 张宏, 张海军.  雀梅藤石油醚提取物诱导三阴性乳腺癌细胞凋亡的实验研究 . 药学实践与服务, 2024, 42(6): 253-259. doi: 10.12206/j.issn.2097-2024.202311055
    [12] 修建平, 杨朝爱, 刘禧澳, 潘乾禹, 韦广旭, 王卫星.  全反式维甲酸对肝星状细胞活化及氧化应激的作用和机制探索 . 药学实践与服务, 2024, 42(7): 291-296. doi: 10.12206/j.issn.2097-2024.202312054
    [13] 姜涛, 徐卫凡, 蒋益萍, 夏天爽, 辛海量.  巴戟天丸组方对Aβ损伤成骨细胞的作用及基于网络药理学的机制研究 . 药学实践与服务, 2024, 42(7): 285-290, 296. doi: 10.12206/j.issn.2097-2024.202305011
    [14] 杨媛媛, 安晓强, 许佳捷, 江键, 梁媛媛.  正极性驻极体联合5-氟尿嘧啶对瘢痕成纤维细胞生长抑制的协同作用 . 药学实践与服务, 2024, 42(6): 244-247. doi: 10.12206/j.issn.2097-2024.202310027
    [15] 唐淑慧, 凤美娟, 薛智霞, 鲁桂华.  帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
    [16] 刘丽艳, 余小翠, 孙传铎.  纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044
    [17] 迟文雅, 袁艳, 李伟林, 吴茼妤, 俞媛.  负载骨髓间充质干细胞/白藜芦醇脂质体的水凝胶支架用于创伤性脑损伤治疗 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202406034
    [18] 宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅.  帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023
    [19] 王耀振, 徐灿, 吕顺莉, 田泾, 张东炜.  钾离子竞争性酸阻滞剂的药学特征研究进展 . 药学实践与服务, 2024, 42(7): 278-284. doi: 10.12206/j.issn.2097-2024.202306040
    [20] 马兹芬, 许维恒, 金煜翔, 薛磊.  食管癌的靶向治疗与免疫治疗研究进展 . 药学实践与服务, 2024, 42(6): 231-237. doi: 10.12206/j.issn.2097-2024.202306008
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  2951
  • HTML全文浏览量:  445
  • PDF下载量:  726
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-01-18
  • 修回日期:  2017-05-31

免疫治疗在肝细胞癌治疗中的进展

doi: 10.3969/j.issn.1006-0111.2017.04.019
  • 第二军医大学附属东方肝胆外科医院肿瘤生物治疗科, 上海 200438
  • 收稿日期: 2017-01-18
  • 修回日期: 2017-05-31

摘要: 肝细胞癌（HCC）是全球发病率和致死率都很高的恶性肿瘤。目前以手术治疗为主的治疗方法远难以达到理想的效果。肿瘤免疫治疗，包括树突状细胞诱导的杀伤细胞（DC-CIK）、肿瘤浸润淋巴细胞（TIL）、嵌合抗原受体T细胞（CAR-T）、免疫检查点阻滞剂（如PD-1阻滞剂、CTL4阻滞剂）等，是近年发展迅速且具有良好前景的肿瘤治疗新方法。本综述着重介绍PD-1阻滞剂、DC-CIK细胞、TIL细胞在治疗肝细胞癌中取得的进展，并对本课题组发明的多能免疫杀伤转基因细胞（PIK）做简要介绍。

English Abstract

郭玲玲, 仇金荣. 免疫治疗在肝细胞癌治疗中的进展[J]. 药学实践与服务, 2017, 35(4): 362-366. doi: 10.3969/j.issn.1006-0111.2017.04.019
引用本文: 郭玲玲, 仇金荣. 免疫治疗在肝细胞癌治疗中的进展[J]. 药学实践与服务, 2017, 35(4): 362-366. doi: 10.3969/j.issn.1006-0111.2017.04.019
shu
GUO Lingling, QIU Jinrong. Progress in immunotherapy for hepatocellular carcinoma[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(4): 362-366. doi: 10.3969/j.issn.1006-0111.2017.04.019
Citation: GUO Lingling, QIU Jinrong. Progress in immunotherapy for hepatocellular carcinoma[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(4): 362-366. doi: 10.3969/j.issn.1006-0111.2017.04.019
shu

    全文HTML

参考文献 (51)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计